Intranasal vaccination of dogs with liver avirulent Bordetella bronchiseptica: correlation of serum agglutination titer and the formation of secretory IgA with protection against experimentally induced infectious tracheobronchitis.
Dogs inoculated intranasally with a live avirulent Bordetella bronchiseptica vaccine were monitored for the development of resistance to experimentally induced infectious tracheobronchitis (canine cough). Dogs were challenge exposed with a virulent strains of B bronchiseptica at various times after they were vaccinated. Clinical protection was detectable as early as 48 hours. At postvaccination days 4, 5, and 14, 56%, 83%, and 95% protection was observed. Humoral immunoglobulin (Ig) titers ranged from 1:8.6 on day 0 to 1:147 on postvaccination day 21. In the monitoring of B bronchiseptica-specific secretory IgA by indirect immunofluorescence, titers appeared as early as day 4 after vaccination. The IgA titers ranged from 1:16 on day 4 to 1: 1,024 on day 21. The appearance of IgA titers correlated with the development of resistance to clinical infection.
D000281:Administration, Intranasal; D000818:Animals; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000276:immunology*; D001884:Bordetella / Q000276:immunology*; D001885:Bordetella Infections / Q000517:prevention & control / Q000662:veterinary*; D001991:Bronchitis / Q000517:prevention & control / Q000662:veterinary*; D004283:Dog Diseases / Q000517:prevention & control*; D004285:Dogs; D007070:Immunoglobulin A / Q000096:biosynthesis*; D007071:Immunoglobulin A, Secretory / Q000096:biosynthesis*; D007136:Immunoglobulins / Q000096:biosynthesis; D014136:Tracheitis / Q000517:prevention & control / Q000662:veterinary*; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology
D001428:Bacterial Vaccines; D007070:Immunoglobulin A; D007071:Immunoglobulin A, Secretory; D007136:Immunoglobulins; D014613:Vaccines, Attenuated